

Applicants : Ron S. Israeli, et al.
U.S. Serial No.: 08/403,803
Filed : March 17, 1995
Page 2

pursue the subject matter of the cancelled claim in a later filed continuation or divisional application.

Please amend claims 59, 77, 79, and 84 by adding the underlined material and deleting the bracketed material as follows:

B²
--59 (Amended) A method of suppressing or modulating metastatic ability of prostate tumor cells, prostate tumor growth or elimination of prostate tumor cells, comprising introducing a DNA molecule of claim 2 [encoding a prostate specific membrane antigen] operatively linked to a 5' regulatory element coupled with a therapeutic DNA into a tumor cell of a subject, thereby suppressing or modulating metastatic ability of prostate tumor cells, prostate tumor growth or elimination of prostate tumor cells.--

B³
--77 (Amended) A therapeutic vaccine for preventing human prostate tumor growth or stimulation of prostate tumor cells in a subject, comprising administering to the subject an effective amount of the cells of claim 74, which expresses or is capable of expressing a prostate specific membrane antigen, and a pharmaceutical acceptable carrier, thereby preventing the tumor growth or stimulation of tumor cells in the subject.--

B⁴
--7 The method of claim [78] 90, wherein the primers are derived from a nucleic acid molecule encoding a prostate specific membrane antigen.--

B⁵
--84 (Amended) A method of abrogating mitogenic response due to transferrin, comprising introducing a DNA molecule of claim 2 [encoding prostate specific membrane antigen] operatively linked to a 5' regulatory element into a tumor cell, the expression

B